Overview Dividends

(KIDS) Orthopediatrics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US68752L1008

Implants, Plates, Screws, Braces, Spine

Health Care Supplies
Market Cap in USD: 440m
IPO / Inception: 2017-10-12
Return 12m vs S&P 500: -34.6%

EPS (Earnings per Share)

EPS (Earnings per Share) of KIDS over the last years for every Quarter: "2020-12": -0.73, "2021-03": -0.47, "2021-06": -0.19, "2021-09": -0.11, "2021-12": -0.24, "2022-03": -0.47, "2022-06": -0.02, "2022-09": -0.07, "2022-12": -0.35, "2023-03": -0.3, "2023-06": -0.13, "2023-09": -0.2, "2023-12": -0.29, "2024-03": -0.34, "2024-06": -0.26, "2024-09": -0.34, "2024-12": -0.29, "2025-03": -0.39, "2025-06": -0.11, "2025-09": -0.24,
EPS CAGR: 0.00%
EPS Trend: -11.1%
Last SUE: 0.09
Qual. Beats: 0

Revenue

Revenue of KIDS over the last years for every Quarter: 2020-12: 18.924, 2021-03: 21.462, 2021-06: 26.695, 2021-09: 25.079, 2021-12: 24.813, 2022-03: 23.417, 2022-06: 32.928, 2022-09: 34.95, 2022-12: 30.994, 2023-03: 31.588, 2023-06: 39.559, 2023-09: 39.972, 2023-12: 37.613, 2024-03: 44.685, 2024-06: 52.802, 2024-09: 54.573, 2024-12: 52.667, 2025-03: 52.411, 2025-06: 61.082, 2025-09: 61.25,
Rev. CAGR: 27.25%
Rev. Trend: 95.3%
Last SUE: -0.91
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 49.7%
Value at Risk 5%th 78.2%
Relative Tail Risk -4.22%
Reward TTM
Sharpe Ratio -0.36
Alpha -40.96
CAGR/Max DD -0.38
Character TTM
Hurst Exponent 0.437
Beta 1.043
Beta Downside 1.262
Drawdowns 3y
Max DD 68.64%
Mean DD 42.62%
Median DD 47.09%

Description: KIDS Orthopediatrics December 27, 2025

OrthoPediatrics Corp. (NASDAQ: KIDS) designs, develops, and markets a full suite of pediatric-specific orthopedic implants, instruments, and braces for trauma, deformity correction, scoliosis, and sports-medicine applications. Its product portfolio includes the PediLoc and PediPlates systems, telescopic intramedullary nails (e.g., Fassier-Duval), growth-modulation devices (GIRO), and specialty braces such as the Boston Brace 3D, serving surgeons and caregivers in the United States and abroad.

Key market indicators suggest upside potential: the U.S. pediatric orthopedic device market is projected to grow at a 6-7% CAGR through 2028, driven by rising rates of childhood sports injuries and earlier detection of spinal deformities. OrthoPediatrics reported FY 2024 revenue of $84 million, up ~14% YoY, and its gross margin expanded to 68% after a cost-efficiency initiative. The company’s cash-burn has fallen to $9 million per quarter, giving it >12 months of runway without additional financing.

If you want a concise, data-rich view of KIDS’s valuation and risk profile, the ValueRay platform provides a quick-look dashboard that can help you assess whether the stock aligns with your risk-return objectives.

Piotroski VR‑10 (Strict, 0-10) 0.5

Net Income (-45.6m TTM) > 0 and > 6% of Revenue (6% = 13.6m TTM)
FCFTA -0.06 (>2.0%) and ΔFCFTA 4.54pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 93.50% (prev 112.7%; Δ -19.16pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.04 (>3.0%) and CFO -19.2m > Net Income -45.6m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 7.40 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (23.4m) change vs 12m ago 1.08% (target <= -2.0% for YES)
Gross Margin 71.73% (prev 73.68%; Δ -1.95pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 46.28% (prev 38.76%; Δ 7.51pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -6.30 (EBITDA TTM -14.4m / Interest Expense TTM 5.38m) >= 6 (WARN >= 3)

Altman Z'' -1.35

(A) 0.43 = (Total Current Assets 245.9m - Total Current Liabilities 33.2m) / Total Assets 493.5m
(B) -0.54 = Retained Earnings (Balance) -265.1m / Total Assets 493.5m
(C) -0.07 = EBIT TTM -33.9m / Avg Total Assets 491.4m
(D) -1.86 = Book Value of Equity -268.7m / Total Liabilities 144.2m
Total Rating: -1.35 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 29.48

1. Piotroski 0.50pt
2. FCF Yield -6.11%
3. FCF Margin -12.94%
4. Debt/Equity 0.28
5. Debt/Ebitda -5.72
6. ROIC - WACC (= -16.06)%
7. RoE -12.97%
8. Rev. Trend 95.35%
9. EPS Trend -11.14%

What is the price of KIDS shares?

As of January 06, 2026, the stock is trading at USD 18.17 with a total of 201,551 shares traded.
Over the past week, the price has changed by +3.06%, over one month by -1.30%, over three months by -0.38% and over the past year by -23.56%.

Is KIDS a buy, sell or hold?

Orthopediatrics has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy KIDS.
  • Strong Buy: 3
  • Buy: 3
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the KIDS price?

Issuer Target Up/Down from current
Wallstreet Target Price 24.1 32.8%
Analysts Target Price 24.1 32.8%
ValueRay Target Price 13.9 -23.4%

KIDS Fundamental Data Overview January 04, 2026

Market Cap USD = 440.4m (440.4m USD * 1.0 USD.USD)
P/S = 1.9364
P/B = 1.275
Beta = 1.061
Revenue TTM = 227.4m USD
EBIT TTM = -33.9m USD
EBITDA TTM = -14.4m USD
Long Term Debt = 99.2m USD (from longTermDebt, last quarter)
Short Term Debt = 166.0k USD (from shortTermDebt, last quarter)
Debt = 99.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 82.5m USD (from netDebt column, last quarter)
Enterprise Value = 482.0m USD (440.4m + Debt 99.3m - CCE 57.7m)
Interest Coverage Ratio = -6.30 (Ebit TTM -33.9m / Interest Expense TTM 5.38m)
FCF Yield = -6.11% (FCF TTM -29.4m / Enterprise Value 482.0m)
FCF Margin = -12.94% (FCF TTM -29.4m / Revenue TTM 227.4m)
Net Margin = -20.06% (Net Income TTM -45.6m / Revenue TTM 227.4m)
Gross Margin = 71.73% ((Revenue TTM 227.4m - Cost of Revenue TTM 64.3m) / Revenue TTM)
Gross Margin QoQ = 73.92% (prev 72.07%)
Tobins Q-Ratio = 0.98 (Enterprise Value 482.0m / Total Assets 493.5m)
Interest Expense / Debt = 1.83% (Interest Expense 1.82m / Debt 99.3m)
Taxrate = 1.05% (-125.0k / -11.9m)
NOPAT = -33.6m (EBIT -33.9m * (1 - 1.05%)) [loss with tax shield]
Current Ratio = 7.40 (Total Current Assets 245.9m / Total Current Liabilities 33.2m)
Debt / Equity = 0.28 (Debt 99.3m / totalStockholderEquity, last quarter 349.3m)
Debt / EBITDA = -5.72 (negative EBITDA) (Net Debt 82.5m / EBITDA -14.4m)
Debt / FCF = -2.80 (negative FCF - burning cash) (Net Debt 82.5m / FCF TTM -29.4m)
Total Stockholder Equity = 351.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -9.24% (Net Income -45.6m / Total Assets 493.5m)
RoE = -12.97% (Net Income TTM -45.6m / Total Stockholder Equity 351.6m)
RoCE = -7.53% (EBIT -33.9m / Capital Employed (Equity 351.6m + L.T.Debt 99.2m))
RoIC = -7.68% (negative operating profit) (NOPAT -33.6m / Invested Capital 437.3m)
WACC = 8.38% (E(440.4m)/V(539.7m) * Re(9.86%) + D(99.3m)/V(539.7m) * Rd(1.83%) * (1-Tc(0.01)))
Discount Rate = 9.86% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 81.65 | Cagr: 4.65%
Fair Price DCF = unknown (Cash Flow -29.4m)
EPS Correlation: -11.14 | EPS CAGR: 0.0% | SUE: 0.09 | # QB: 0
Revenue Correlation: 95.35 | Revenue CAGR: 27.25% | SUE: -0.91 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.39 | Chg30d=+0.056 | Revisions Net=+0 | Analysts=5
EPS next Year (2026-12-31): EPS=-1.03 | Chg30d=+0.173 | Revisions Net=+0 | Growth EPS=+0.3% | Growth Revenue=+12.4%

Additional Sources for KIDS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle